Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer

Shuanshuan Xie; Changxing Shen; Min Tan; Ming Li; Xiaolian Song; Changhui Wang

doi:10.18632/oncotarget.16111

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer

Shuanshuan Xie, Changxing Shen, Min Tan, Ming Li, Xiaolian Song and Changhui Wang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:27216-27239. https://doi.org/10.18632/oncotarget.16111

Metrics: PDF 2139 views | HTML 2921 views | ?

Abstract

Shuanshuan Xie1, Changxing Shen1, Min Tan1, Ming Li1, Xiaolian Song1, Changhui Wang1

1Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China

Correspondence to:

Changhui Wang, email: [email protected]

Keywords: adenylate cyclase-associated protein, copy number alteration, mutation, overall survival

Received: July 07, 2016 Accepted: February 20, 2017 Published: March 10, 2017

ABSTRACT

Adenylate Cyclase-associated protein (CAP) is an evolutionarily conserved protein that regulates actin dynamics. Our previous study indicates that CAP1 is overexpressed in NSCLC tissues and correlated with poor clinical outcomes, but CAP1 in HeLa cells actually inhibited migration and invasion, the role of CAP was discrepancy in different cancer types. The present study aims to determine whether CAP can serve as a prognostic marker in human cancers. The CAP expression was assessed using Oncomine database to determine the gene alteration during carcinogenesis, the copy number alteration, or mutations of CAP using cBioPortal, International Cancer Genome Consortium, and Tumorscape database investigated, and the association between CAP expression and the survival of cancer patient using Kaplan-Meier plotter and PrognoScan database evaluated. Therefore, the functional correlation between CAP expression and cancer phenotypes can be established; wherein CAP might serve as a diagnostic marker or therapeutic target for certain types of cancers.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16111

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer

Abstract